Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZoetisXSWX:ZTS +0.79%56 3-Year EPS without NRI Growth Rate is 9.50% as of Jun. 2026, which is 57% below its 10-year median of 21.90. GuruFocus rates XSWX:ZTS with a GF Score™ of 56/100 and a GF Value™ of CHF147.84 (Significantly Undervalued). Among 786 Drug Manufacturers companies, Zoetis ranks worse than 51.27% on this metric.
During the past 12 months, Zoetis's average EPS without NRI Growth Rate was 5.40% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 9.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 10.00% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 14.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Zoetis was 66.20% per year. The lowest was 8.00% per year. And the median was 21.90% per year.
Zoetis (XSWX:ZTS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Zoetis 3-Year EPS without NRI Growth Rate Related Terms
XSWX:ZTS vs UTHR, VTRS, NBIX: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Zoetis's 3-Year EPS without NRI Growth Rate falls into.
Zoetis 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 9.50% mean?
Zoetis (XSWX:ZTS) has a 3-Year EPS without NRI Growth Rate of 9.50% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Zoetis and its competitors. This is 57% below median its historical median of 21.90. Over the past decade, Zoetis' 3-Year EPS without NRI Growth Rate has ranged from 8.00 to 66.20. According to the industry distribution chart, Zoetis ranks #403 out of 786 companies in the Drug Manufacturers industry, placing it in the top 51.3%.
Is Zoetis' 3-Year EPS without NRI Growth Rate too high?
Zoetis' current 3-Year EPS without NRI Growth Rate of 9.50% is 57% below median its 10-year median of 21.90. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 66.20. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.85. Zoetis' value of 9.50% is 3.6% below this industry median. Based on the distribution chart, Zoetis ranks #403 out of 786 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zoetis has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' 3-Year EPS without NRI Growth Rate compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #403 out of 786 companies for 3-Year EPS without NRI Growth Rate. This places Zoetis in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.85. Zoetis' value of 9.50% is 3.6% below this benchmark. Historically, Zoetis' own 3-Year EPS without NRI Growth Rate has ranged from 8.00 to 66.20 over the past decade. While the company's 10-year median is 21.90 vs. the industry median of 9.85, Zoetis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.85, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zoetis's current 3-Year EPS without NRI Growth Rate of 9.50% is 3.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Zoetis and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current 3-Year EPS without NRI Growth Rate is 9.50%, which is 57% below median its own 10-year median of 21.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF147.84, compared to a current price of CHF61.26 — trading 58.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 9.50%, which is 57% below median its 10-year median of 21.90 and 3.6% below the Drug Manufacturers industry median of 9.85. Zoetis' overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current 3-Year EPS without NRI Growth Rate is 9.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (XSWX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of CHF61.26 is trading 58.6% below its estimated GF Value™ of CHF147.84.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for XSWX:ZTS:
3-Year EPS without NRI Growth Rate: 9.50% (57% below median its 10-year median of 21.90)
GF Value™: CHF147.84 vs. price of CHF61.26 (58.6% below fair value)
Industry Position: 3.6% below the Drug Manufacturers median (#403 of 786)
No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
56GF Score
Get the complete analysis for XSWX:ZTS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZTS has been successfully added to your 
